IMAGENE Co., Ltd. researches and develops treatment for cancer and infectious diseases. Its products include antibody43, chiral building blocks, and aminoacyl-tRNA synthetase inhibitors. The company was founded on December 1, 1997 and is headquartered in Yongin, South Korea.

Shanghai Bode Gene Development Co., Ltd., established on 1998-03-22, Business scope includes bioengineering,Technology transfer in the field of genetic engineering expertise,technology development,technical consulting,Technical services and manufacture of related reagents and equipment,Sales;Bioengineering and Genetic Engineering Products,electronics,Chemical Products(In addition to dangerous goods)import and export business. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Riken Corp. engages in the manufacture and sale of engine and vehicular components. It operates through the Automotive and Machinery Parts, and Others segments. The Automotive and Machinery Parts segment deals with the company's core products such as piston rings, camshafts, seal rings for transmissions, high-grade cast iron products, and valve lifters. The Others segment includes plumbing equipment business, Electromagnetic Compatibility (EMC) business, and thermal engineering business, The company was founded by Masatoshi Okochi in November 1927 and is headquartered in Tokyo, Japan.

InhibOx is a pioneer in the development and application of new technologies to drive drug discovery. Their multidisciplinary research team has brought together breakthroughs in computational chemistry, cheminformatics, mathematics, cloud computing and software-as-a-service (SaaS) delivery methods to create DrugFinder: the next generation drug discovery platform.

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Unitika Ltd. engages in the polymer and functional materials business. It operates through the following business segments: Polymer, Functional Material, Fiber, and Others. The Polymer segment manufactures and sells plastic film, resin, and non-woven cloth. The Functional Material segment handles the manufacture and sale of glass fibers. The Fiber segment deals with the manufacture and sale of various fibers such as thread, cotton, and knitted fibers. The Others segment includes environmental business, medical business, lifestyle and wellness, and real estate businesses. The company was founded on June 19, 1889 and is headquartered in Osaka, Japan.

Seoul National University Hospital (서울대학교병원) is one of the oldest and biggest hospitals in South Korea. It is a general and teaching hospital of Seoul National University's College of Medicine. Except SNUH Healthcare System Gangnam Center, all branches have an emergency department (ED).

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.

DuPont offers sustainable solutions for agriculture, electronics, communications, construction, transportation, and apparel markets. Their products and services include construction materials, fabrics, packaging materials, medical devices, electronic solutions, and adhesives for markets. They provide specialized construction materials to create and maintain roads, bridges, telecommunications, power, and water plants.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

In October 2010, Gene Frontier took a new step as a member of the Kaneka Group. Former Gene Frontier, the predecessor, has been striving as a leading domestic company in the microarray business and antibody-related business since its establishment in 2003. Since 2008, the company has focused on protein and antibody-related businesses. In antibody-related businesses, we have been developing business in close collaboration with our partner partner MorphoSys. In recent years, antibody drugs have been able to specifically attack proteins that become disease-related factors by utilizing the inherent property of antibodies that bind only to target cells such as cancer cells, and have a breakthrough with fewer side effects. Because of the therapeutic effects, development competition is occurring worldwide. We use fully artificial recombinant human antibody production technology introduced from Germany's MorphoSys to promote antibody drug target search business through joint research with other companies and other organizations, and licensing to Japanese bio-drug discovery companies. We are actively working to further accelerate biopharmaceutical research and development. Gene Frontier has expanded its business domains that lead to the acceleration of biopharmaceuticals including antibody drugs, and is also developing its own technologies. In the future, with the support of Kaneka, we will accelerate research and development and business development, and aim for further growth toward the world. Gene Frontier shares Kaneka's corporate vision, “To be more surprised, to Mirai.” And will continue to provide unique technologies and services for the development of innovative medicines and diagnostics. As a partner, we will contribute to medical treatment in the 21st century.

Shenzhen Shengbizhi Technology Development Co., Ltd., established on 2013-03-12, Business scope includes general business items:Technology development of computer software,Sales;biotechnology research,Biosensor Development;Technical research and development of medical kit products;Medical software development;Operating import and export business.(above laws,Administrative regulations,Except for items that are subject to approval prior to registration by decision of the State Council,Restricted projects must obtain a license before operating),The licensing program is:R&D and sales of Class II medical devices.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Hangzhou Jiahua Hesheng Pharmaceutical Technology Co., Ltd, established on 2022-03-16, Business scope includes general items:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Graphic design and production;Advertising Design,acting;advertising;Organize cultural and artistic exchange activities;Conference and Exhibition Services;Science popularization service;Natural science research and experimental development;Professional Design Services;Production of protective equipment for medical personnel(Ι class medical device);Sales of Class I Medical Devices;Class I Medical Device Leasing;Chemical product production(No licensed chemical products);Chemical product sales(No licensed chemical products);Biochemical product technology research and development;Machinery sales;Manufacturing of special equipment(Manufacture of licensed professional equipment not included);Mechanical equipment research and development;Corporate Image Planning;Socioeconomic Advisory Services;Information Consulting Service(Not including licensing information consulting services);Consulting and planning service;translation service(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).